Will restructuring US biz turnaround this pharma player?

In a regulatory filing, the company said it is closing down its manufacturing facility in Illinois, USA and will continue its business in the United States through contract manufacturing alliances for its products sold in North America.The drugmaker also said that the new arrangement is in the interest of the company as it will help avoid the manufacturing and quality management cost completely resulting in significant savings in operating and overhead costs.